ATE359798T1 - Verwendungvon dextransulfat zur behandlung von ibmir - Google Patents

Verwendungvon dextransulfat zur behandlung von ibmir

Info

Publication number
ATE359798T1
ATE359798T1 AT03811973T AT03811973T ATE359798T1 AT E359798 T1 ATE359798 T1 AT E359798T1 AT 03811973 T AT03811973 T AT 03811973T AT 03811973 T AT03811973 T AT 03811973T AT E359798 T1 ATE359798 T1 AT E359798T1
Authority
AT
Austria
Prior art keywords
dextransulphate
ibmir
treat
human patient
cell transplant
Prior art date
Application number
AT03811973T
Other languages
English (en)
Inventor
Bo Nilsson
Olle Korsgren
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Application granted granted Critical
Publication of ATE359798T1 publication Critical patent/ATE359798T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03811973T 2002-11-28 2003-11-26 Verwendungvon dextransulfat zur behandlung von ibmir ATE359798T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat

Publications (1)

Publication Number Publication Date
ATE359798T1 true ATE359798T1 (de) 2007-05-15

Family

ID=20289705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03811973T ATE359798T1 (de) 2002-11-28 2003-11-26 Verwendungvon dextransulfat zur behandlung von ibmir

Country Status (26)

Country Link
US (5) US8629123B2 (de)
EP (1) EP1567171B1 (de)
JP (2) JP4315908B2 (de)
KR (1) KR100828807B1 (de)
CN (1) CN1296051C (de)
AT (1) ATE359798T1 (de)
AU (1) AU2003302378B2 (de)
BR (1) BRPI0316666B8 (de)
CA (1) CA2507595C (de)
CY (1) CY1106739T1 (de)
DE (1) DE60313356T2 (de)
DK (1) DK1567171T3 (de)
EA (1) EA010409B1 (de)
ES (1) ES2285270T3 (de)
HK (1) HK1087042A1 (de)
HR (1) HRP20050439B1 (de)
IL (1) IL168626A (de)
IS (1) IS2405B (de)
NO (1) NO326946B1 (de)
NZ (1) NZ540744A (de)
PL (1) PL216067B1 (de)
PT (1) PT1567171E (de)
SE (1) SE525461C3 (de)
SI (1) SI1567171T1 (de)
WO (1) WO2004047848A1 (de)
ZA (1) ZA200504111B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046162A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
WO2008153962A2 (en) * 2007-06-08 2008-12-18 The Trustees Of The University Of Pennylvania Method of reducing tissue loss in pancreatic islet cell transplantation
EP2550004A4 (de) * 2010-03-12 2014-07-02 Univ Australian Heparansulfatersatztherapie
HUE044196T2 (hu) * 2010-07-16 2019-10-28 Tx Medic Ab Sejtterápia
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
SE537742C2 (sv) * 2013-05-13 2015-10-13 Tx Medic Ab Dextransulfat för cellmobilisering
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
KR102015197B1 (ko) * 2014-06-12 2019-08-27 티엑스 메딕 에이비 대상체에서의 혈관신생을 유도하기 위한 10000Da 미만의 평균 분자량을 가지는 황산덱스트란의 용도
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
JP2020533281A (ja) * 2017-09-08 2020-11-19 ティーエックス メディック エービー デキストラン硫酸の新規使用
KR20230002698A (ko) * 2020-04-15 2023-01-05 티엑스 메딕 에이비 패혈증 및 과다사이토카인분비증의 치료
SE544768C2 (en) * 2021-03-24 2022-11-08 Tx Medic Ab Combination for treatment of thromboinflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
TW318142B (de) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CN1178070A (zh) * 1996-09-27 1998-04-08 刘春江 组织脏器移植用保存溶液·手术等时组织脏器保护溶液
CN1057192C (zh) * 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法

Also Published As

Publication number Publication date
NO20052505L (no) 2005-06-20
ZA200504111B (en) 2006-07-26
CY1106739T1 (el) 2012-05-23
US8906884B2 (en) 2014-12-09
HRP20050439B1 (en) 2007-11-30
US8901104B2 (en) 2014-12-02
IL168626A (en) 2011-06-30
US20140094435A1 (en) 2014-04-03
SI1567171T1 (sl) 2007-08-31
HK1087042A1 (en) 2006-10-06
US8629123B2 (en) 2014-01-14
EA010409B1 (ru) 2008-08-29
ES2285270T3 (es) 2007-11-16
NZ540744A (en) 2007-02-23
AU2003302378A1 (en) 2004-06-18
NO326946B1 (no) 2009-03-16
JP2009167201A (ja) 2009-07-30
EP1567171B1 (de) 2007-04-18
AU2003302378B2 (en) 2008-02-21
US20160136331A1 (en) 2016-05-19
CA2507595A1 (en) 2004-06-10
EP1567171A1 (de) 2005-08-31
JP4972113B2 (ja) 2012-07-11
PL216067B1 (pl) 2014-02-28
IS2405B (is) 2008-09-15
PT1567171E (pt) 2007-07-09
US20060111319A1 (en) 2006-05-25
US20140093484A1 (en) 2014-04-03
CN1296051C (zh) 2007-01-24
KR100828807B1 (ko) 2008-05-09
CN1717240A (zh) 2006-01-04
US20100113389A1 (en) 2010-05-06
BRPI0316666B1 (pt) 2018-09-25
US10307440B2 (en) 2019-06-04
KR20050089803A (ko) 2005-09-08
SE0203526D0 (sv) 2002-11-28
DE60313356T2 (de) 2007-08-16
HRP20050439A2 (en) 2005-12-31
IS7908A (is) 2005-06-23
CA2507595C (en) 2011-11-08
SE525461C2 (sv) 2005-02-22
US9364499B2 (en) 2016-06-14
BRPI0316666B8 (pt) 2021-05-25
SE525461C3 (sv) 2005-03-23
SE0203526L (sv) 2004-05-29
JP4315908B2 (ja) 2009-08-19
DE60313356D1 (de) 2007-05-31
JP2006509057A (ja) 2006-03-16
WO2004047848A1 (en) 2004-06-10
EA200500757A1 (ru) 2005-12-29
PL376302A1 (en) 2005-12-27
BR0316666A (pt) 2005-10-11
DK1567171T3 (da) 2007-07-16

Similar Documents

Publication Publication Date Title
NO20052505L (no) Ny bruk av dextran-sulfat
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ATE297169T1 (de) Auffindbare künstliche bioimplantate
WO2002002593A3 (en) Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
EP2767291A3 (de) Behandlung der Glykogenspeicherkrankheit Typ II
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
EP2364708A3 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG, ENTHALTEND EINEN ClC-2-CHANNEL-AKTIVATOR
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DK1569679T3 (da) Chaperonin-10-immunosuppression
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
HUP0203486A2 (hu) Véralvadással összefüggő betegségek megelőzése és kezelése
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
WO1998024898A3 (en) Therapeutic composition comprising the kal protein and use of the kal protein
DE69904712D1 (de) Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
MD1135F1 (en) Paradontium treatment method
RU99111148A (ru) Глазные капли
RU2005102040A (ru) Искусственная биокожа "ростоши"
MD2876B1 (en) Biostimulating remedy of the locomotor system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1567171

Country of ref document: EP